Company intelligence / Profile preview
Processa Pharmaceuticals, Inc.
Hanover, Maryland, United Statesprocessapharma.com ↗
- Ownership
- Public · PCSA
- Employees
- ~11-50
- Development stage
- Other
01
Overview
Processa's lead candidate NGC-Cap is in Phase 2 clinical trials for metastatic breast cancer with initial data readout expected in mid-2025. NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity. Preclinical studies for NGC-Iri showed it delivers more cancer-killing SN-38 molecules to tumors than either irinotecan or Onivyde.
- Therapeutic areas
- GastroenterologyOncologyDermatology
- Modalities
- Small moleculesNext Generation Chemotherapy (NGC)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Financials
- Market cap
- $5.1M
- Total revenue
- $0
- Enterprise value
- $5M
Beyond the preview
Go deeper on Processa Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Processa Pharmaceuticals, Inc..